{"id":"NCT01462812","sponsor":"Optinose US Inc.","briefTitle":"Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine With or Without Aura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2011-10-31","resultsPosted":"2015-05-06","lastUpdate":"2015-05-06"},"enrollment":223,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Headache"],"interventions":[{"type":"DRUG","name":"Sumatriptan","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sumatriptan","type":"ACTIVE_COMPARATOR"},{"label":"Matching placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN Device can reduce the pain and symptoms associated with migraine headaches.","primaryOutcome":{"measure":"Headache Relief","timeFrame":"120 Minutes","effectByArm":[{"arm":"Matching Placebo","deltaMin":47,"sd":null},{"arm":"Sumatriptan","deltaMin":73,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":["25355310"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":111},"commonTop":["Product Taste Abnormal","Nasal Discomfort","Rhinorrhoea","Rhinitis"]}}